Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
GenEdit, a US-based genetic medicine developer based on research at University of California (UC), Berkeley, has completed a $26m series A round featuring the UC-aligned venture capital fund Bow Capital. The round also included pharmaceutical firm Eli Lilly, conglomerate SK, KTB Network, Company K Partners, Korea Investment Partners, Dayli Partners, KB Investment, IMM Investment, TimeFolio Asset Management, DCVC Bio and Sequoia Capital. The spinout had raised $8.5m in a 2018 seed round co-led by SK and DCVC Bio that included…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
